PURPOSE: The effectiveness of vaccines depends on the age and immunocompetence of the vaccinee. Conventional non-adjuvanted influenza vaccines are suboptimal in the elderly and vaccines with improved ability to prevent influenza are required. The TLR4 agonist E6020, either given alone or co-delivered with MF59, was evaluated and compared to MF59 and the TLR9 agonist CpG. Its ability to enhance antibody titres and to modulate the quality of the immune response to a subunit influenza vaccine was investigated. METHODS: Mice were immunized with either antigens alone, with MF59 or with the TLR agonists alone, or with a combination thereof. Serum samples were assayed for IgG antibody titres and hemagglutination inhibition (HI) titres. Th1/Th2 type responses were determined by titrating IgG subclasses in serum samples and by T-cell cytokine responses in splenocytes. RESULTS: MF59 was the best single adjuvant inducing HI and T-cell responses in comparison to all alternatives. The co-delivery of E6020 or CpG with MF59 did not further increase antibody titres however shifted towards a more Th1 based immune response. CONCLUSION: Combining adjuvants like E6020 and MF59 allowed a finer tuning of the immune response towards a particular Th bias, thus have significant implications for the development of improved influenza vaccines.
PURPOSE: The effectiveness of vaccines depends on the age and immunocompetence of the vaccinee. Conventional non-adjuvanted influenza vaccines are suboptimal in the elderly and vaccines with improved ability to prevent influenza are required. The TLR4 agonist E6020, either given alone or co-delivered with MF59, was evaluated and compared to MF59 and the TLR9 agonist CpG. Its ability to enhance antibody titres and to modulate the quality of the immune response to a subunit influenza vaccine was investigated. METHODS:Mice were immunized with either antigens alone, with MF59 or with the TLR agonists alone, or with a combination thereof. Serum samples were assayed for IgG antibody titres and hemagglutination inhibition (HI) titres. Th1/Th2 type responses were determined by titrating IgG subclasses in serum samples and by T-cell cytokine responses in splenocytes. RESULTS: MF59 was the best single adjuvant inducing HI and T-cell responses in comparison to all alternatives. The co-delivery of E6020 or CpG with MF59 did not further increase antibody titres however shifted towards a more Th1 based immune response. CONCLUSION: Combining adjuvants like E6020 and MF59 allowed a finer tuning of the immune response towards a particular Th bias, thus have significant implications for the development of improved influenza vaccines.
Authors: Sandra L Giannini; Emmanuel Hanon; Philippe Moris; Marcelle Van Mechelen; Sandra Morel; Francis Dessy; Marc A Fourneau; Brigitte Colau; Joann Suzich; Genevieve Losonksy; Marie-Thérèse Martin; Gary Dubin; Martine A Wettendorff Journal: Vaccine Date: 2006-06-19 Impact factor: 3.641
Authors: Nigel Bourne; Gregg N Milligan; Lawrence R Stanberry; Rachael Stegall; Richard B Pyles Journal: J Infect Dis Date: 2005-11-11 Impact factor: 5.226
Authors: Andreas Wack; Barbara C Baudner; Anne K Hilbert; Ilaria Manini; Sandra Nuti; Simona Tavarini; Hanno Scheffczik; Mildred Ugozzoli; Manmohan Singh; Jina Kazzaz; Emanuele Montomoli; Giuseppe Del Giudice; Rino Rappuoli; Derek T O'Hagan Journal: Vaccine Date: 2007-12-07 Impact factor: 3.641
Authors: Crina Stavaru; Adrian Onu; Emilia Lupulescu; Catalin Tucureanu; Orhan Rasid; Ene Vlase; Cristin Coman; Iuliana Caras; Alina Ghiorghisor; Laurentiu Berbecila; Vlad Tofan; Richard A Bowen; Nicole Marlenee; Airn Hartwig; Helle Bielefeldt-Ohmann; Susan L Baldwin; Neal Van Hoeven; Thomas S Vedvick; Chuong Huynh; Michael K O'Hara; Diana L Noah; Christopher B Fox Journal: Hum Vaccin Immunother Date: 2015-11-30 Impact factor: 3.452
Authors: Joseph R Francica; Daniel E Zak; Caitlyn Linde; Emilio Siena; Carrie Johnson; Michal Juraska; Nicole L Yates; Bronwyn Gunn; Ennio De Gregorio; Barbara J Flynn; Nicholas M Valiante; Padma Malyala; Susan W Barnett; Pampi Sarkar; Manmohan Singh; Siddhartha Jain; Margaret Ackerman; Munir Alam; Guido Ferrari; Andres Salazar; Georgia D Tomaras; Derek T O'Hagan; Alan Aderem; Galit Alter; Robert A Seder Journal: Blood Adv Date: 2017-11-17
Authors: Katharina Richard; Darren J Perkins; Erin M Harberts; Yang Song; Archana Gopalakrishnan; Kari Ann Shirey; Wendy Lai; Alexandra Vlk; Anup Mahurkar; Shreeram Nallar; Lynn D Hawkins; Robert K Ernst; Stefanie N Vogel Journal: Vaccine Date: 2020-05-07 Impact factor: 3.641
Authors: Eric Dumonteil; Maria Elena Bottazzi; Peter J Hotez; Bin Zhan; Michael J Heffernan; Kathryn Jones; Jesus G Valenzuela; Shaden Kamhawi; Jaime Ortega; Samuel Ponce de Leon Rosales; Bruce Y Lee; Kristina M Bacon; Bernhard Fleischer; B T Slingsby; Miguel Betancourt Cravioto; Roberto Tapia-Conyer Journal: Expert Rev Vaccines Date: 2012-09 Impact factor: 5.217
Authors: Christopher H Clegg; Richard Roque; Neal Van Hoeven; Lucy Perrone; Susan L Baldwin; Joseph A Rininger; Richard A Bowen; Steven G Reed Journal: Proc Natl Acad Sci U S A Date: 2012-10-08 Impact factor: 11.205